Patient and Clinician Perspectives on Preventive Therapy for Migraine

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Prevalence of Migraine

Migraine History

Diagnosing Migraine

CM and Medication Overuse

Risk Factors Associated With Progression of CM

How Does Chronification of Migraine Occur?

Preventive Treatment

What Is CGRP and What Role Does It Play in Migraine?

CGRP Receptor Complex

Anti-CGRP Monoclonal Antibodies in Development

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Eptinezumab for Prevention of CM

Phase 3 REGAIN Study of Galcanezumab in Patients With CM

Early Results of Phase 3 HALO Trial for Fremanezumab

Phase 2: Prevention of CM With Erenumab

Conclusion

Questions?

Abbreviations

Abbreviations (cont)